Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi): Worried about the remainder of 2019 (?), think nine (9) factors…

May 20, 2019

Volatility, algorithms, sustainability … how are enrollments going as to population and is data from on-going trials being interpreted to render measurable and definitive outcomes? Add to the list, trend analysis, momentum’s magnitude, technicals and fundamentals – do they indicate expected pricing performance in 2019? Why spend time finding sector news and analytics … it’s all right here! 

Regenerative Medicine Earnings Scorecard - Q1/19 - to date

May 19, 2019

A scorecard of earnings of 45 covered  companies 41 so far: 2 acquired (AST, OSIR) 1 on acquisition hold - ONCE) and 1 set to be reversed (HSGX) ... The current LPS (loss per share) or net income, cash positions i.e. "runways" - is a reflection of this universe's investing "status"  

Regenerative Medicine Earnings Scorecard - Q4/18 and FY18 - to date

March 31, 2019

A scorecard of  (AKA) earnings of 45 covered  companies 44 out of 45 ...   The current LPS (loss per share) or net income, cash positions i.e. "runways" - it's a reflection of this universe's investing "status"